Compare KO & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KO | NVO |
|---|---|---|
| Founded | 1886 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 376.9B | 199.4B |
| IPO Year | 2004 | 2001 |
| Metric | KO | NVO |
|---|---|---|
| Price | $88.42 | $43.14 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 16 | 11 |
| Target Price | ★ $84.13 | $51.00 |
| AVG Volume (30 Days) | ★ 12.9M | 9.4M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | 2.69% | ★ 3.19% |
| EPS Growth | ★ 23.58 | N/A |
| EPS | ★ 0.91 | N/A |
| Revenue | ★ $47,941,000,000.00 | N/A |
| Revenue This Year | $5.29 | N/A |
| Revenue Next Year | $1.77 | $3.70 |
| P/E Ratio | $96.21 | ★ $13.60 |
| Revenue Growth | ★ 1.87 | N/A |
| 52 Week Low | $65.35 | $35.12 |
| 52 Week High | $92.49 | $64.16 |
| Indicator | KO | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 50.05 | 39.58 |
| Support Level | $85.41 | $43.29 |
| Resistance Level | $90.92 | $51.38 |
| Average True Range (ATR) | 1.16 | 0.90 |
| MACD | -0.43 | -0.16 |
| Stochastic Oscillator | 12.60 | 0.00 |
Founded in 1886, Atlanta-headquartered Coca-Cola is the world's largest nonalcoholic beverage company, with a strong portfolio of 200 brands covering key categories including carbonated soft drinks, water, sports, energy, juice, and coffee. Together with bottlers and distribution partners, the company sells finished beverage products bearing Coca-Cola and licensed brands through retailers and food-service locations in more than 200 countries and regions globally. Coca-Cola generates around 60% of its total revenue overseas, with sizable contributions from emerging economies in Latin America and Asia-Pacific.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.